Abstract
Multidrug resistance in cancer cells is often associated with an elevation in the concentration of glutathione (GSH) and the expression of γ-glutamylcysteine synthetase (γ-GCS), a rate-limiting enzyme for GSH. We constructed a hammerhead ribozyme against a γ-GCS heavy subunit (γ-GCSh) mRNA transcript and transfected it to human colonic cancer cells (HCT8DDP) resistant to cisplatin (CDDP). The effect of the ribozyme transfection on the drug resistance of cancer cells was studied. (a) Transfection of the ribozyme decreased the GSH level and the efflux of CDDP–GSH adduct, resulting in higher sensitivity of the cells to CDDP. (b) The transfection suppressed the expression of ATP-binding cassette (ABC) family of transporters such as MRP1, MRP2, and MDR1, and stimulated the expression of mutant p53. (c) An electrophoretic mobility shift assay showed that mutant p53 suppresses the SP1–DNA binding activity, suggesting that this mutant p53 is functional and it, in turn, suppresses the expression of ABC transporters. Collectively, transfection of anti–γ-GCSh ribozyme reduced the synthesis of GSH and the expression of ABC transporters, which causes an increase in the sensitivity of cancer cells to anticancer drugs. Suppression of the SP1–DNA binding activity by p53 may be a factor of down-regulation of ABC transporters. Cancer Gene Therapy (2001) 8, 803–814
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Meister A . Methods for the selective modification of glutathione metabolism and study of glutathione transport Methods Enzymol 1985 113: 571–585
Kondo T, Yoshida K, Urata Y, et al . Gamma-glutamylcysteine synthetase and active transport of glutathione S-conjugate are responsive to heat shock in K562 erythroid cells J Biol Chem 1993 268: (27) 20366–20372
Urata Y, Yamamoto H, Goto S, et al . Long exposure to high glucose concentration impairs the responsive expression of gamma-glutamylcysteine synthetase by interleukin-1 beta and tumor necrosis factor-alpha in mouse endothelial cells J Biol Chem 1996 271: (25) 15146–15152
Beutler E, Gelbart T, Kondo T, et al . The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency Blood 1999 94: (8) 2890–2894
Yan N, Meister A . Amino acid sequence of rat kidney γ-glutamylcysteine synthetase J Biol Chem 1990 265: 1588–1593
Iida T, Mori E, Mori K, et al . Co-expression of gamma-glutamylcysteine synthetase subunits in response to cisplatin and doxorubicin in human cancer cells Int J Cancer 1999 82: (3) 405–411
Goto S, Yoshida K, Morikawa T, et al . Augmentation of transport for cisplatin–glutathione adduct in cisplatin-resistant cancer cells Cancer Res 1995 55: (19) 4297–4301
Goto S, Iida T, Cho S, et al . Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells Free Radical Res 1999 31: (6) 549–558
Godwin AK, Meister A, O'Dwyer PJ, et al . High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc Natl Acad Sci USA 1992 89: (7) 3070–3074
Yao KS, Godwin AK, Johnson SW, et al . Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines Cancer Res 1995 55: (19) 4367–4374
Kuo MT, Bao J, Furuichi M, et al . Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues Biochem Pharmacol 1998 55: (5) 605–615
Ogretmen B, Bahadori HR, McCauley MD, et al . Co-ordinated over-expression of the MRP and gamma-glutamylcysteine synthetase genes, but not MDR1, correlates with doxorubicin resistance in human malignant mesothelioma cell lines Int J Cancer 1998 75: (5) 757–761
Cole SP, Bhardwaj G, Gerlach JH, et al . Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 1992 258: (5088) 1650–1654
Kool M, de Haas M, Scheffer GL, et al . Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance–associated protein gene (MRP1), in human cancer cell lines Cancer Res 1997 57: (16) 3537–3547
Hour TC, Chen J, Huang CY, et al . Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cells lines Anticancer Res 2000 20: (5A) 3221–3225
Borst P, Evers R, Kool M, et al . A family of drug transporters: the multidrug resistance–associated proteins J Natl Cancer Inst 2000 92: (16) 1295–1302
Hinoshita E, Uchiumi T, Taguchi K, et al . Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas Clin Cancer Res 2000 6: (6) 2401–2407
Schrenk D, Baus PR, Ermel N, et al . Up-regulation of transporters of the MRP family by drugs and toxins Toxicol Lett 2001 120: (1–3) 51–57
Materna V, Holm PS, Dietel M, et al . Kinetic characterization of ribozymes directed against the cisplatin resistance–associated ABC transporter cMOAT/MRP2/ABCC2 Cancer Gene Ther 2001 8: (3) 176–184
Manna SK, Kuo MT, Aggarwal BB . Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1 Oncogene 1999 18: 4371–4382
Gomi A, Shinoda S, Masuzawa T, et al . Transient induction of the MRP/GS-X pump and gamma-glutamylcysteine synthetase by 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea in human glioma cells Cancer Res 1997 57: (23) 5292–5299
Yamane Y, Furuichi M, Song R, et al . Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress J Biol Chem 1998 273: (47) 31075–31085
Scanlon KJ, Ishida H, Kashani-Sabet M . Ribozyme-mediated reversal of the multidrug-resistant phenotype Proc Natl Acad Sci USA 1994 91: (23) 11123–11127
Kashani-Sabet M, Funato T, Florenes VA, et al . Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme Cancer Res 1994 54: (4) 900–902
Haseloff J, Gerlach WL . Simple RNA enzymes with new and highly specific endoribonuclease activities Nature 1988 334: (6183) 585–591
Scanlon KJ, Ohta Y, Ishida H, et al . Oligonucleotide-mediated modulation of mammalian gene expression FASEB J 1995 9: (13) 1288–1296
Kijima H, Tsuchida T, Kondo H, et al . Hammerhead ribozymes against gamma-glutamylcysteine synthetase mRNA down-regulate intracellular glutathione concentration of mouse islet cells Biochem Biophys Res Commun 1998 247: (3) 697–703
Beutler E . A manual of biochemical methods In: Beutler E, ed., Red Cell Metabolism, 3rd edn Orlando: Grune and Stratton 1984 72–136
Abbaszadegan MR, Futscher BW, Klimecki WT, et al . Analysis of multidrug resistance–associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells Cancer Res 1994 54: (17) 4676–4679
Narasaki F, Oka M, Nakano R, et al . Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells Biochem Biophys Res Commun 1997 240: (3) 606–611
Narasaki F, Matsuo I, Ikuno N, et al . Multidrug resistance–associated protein (MRP) gene expression in human lung cancer Anticancer Res 1996 16: (4A) 2079–2082
Wang Q, Beck WT . Transcriptional suppression of multidrug resistance–associated protein (MRP) gene expression by wild-type p53 Cancer Res 1998 58: (24) 5762–5769
Sambrook J, Fritsch EF, Maniatis T . Molecular Cloning: A Laboratory Manual 2nd edn Cold Spring Harbor, NY: Cold Spring Harbor Laboratory 1989
Abmayr SM, Warkman JL . Current Protocols in Molecular Biology New York: Greene Publishing Associates and Wiley-Interscience 1987
Sen R, Baltimore D . Multiple nuclear factors interact with the immunoglobulin enhancer sequences Cell 1986 46: (5) 705–716
Zhu Q, Center MS . Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin Cancer Res 1994 54: (16) 4488–44892
Grant CE, Valdimarsson G, Hipfner DR, et al . Overexpression of multidrug resistance–associated protein (MRP) increases resistance to natural product drugs Cancer Res 1994 54: (2) 357–361
Redinbaugh MG, Turley RB . Adaptation of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions Anal Biochem 1986 153: (2) 267–271
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 1983 65: (1–2) 55–63
Caserini C, Pratesi G, Tortoreto M, et al . Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro / in vivo studies Clin Cancer Res 1997 3: (6) 955–961
Koike K, Kawabe T, Tanaka T, et al . A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells Cancer Res 1997 57: (24) 5475–5479
Tipnis SR, Blake DG, Shepherd G, et al . Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance Biochem J 1999 337: 559–566
Zhang K, Chew M, Yang EB, et al . Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms Mol Pharmacol 2001 59: (4) 837–843
Hour TC, Chen J, Huang CY, et al . Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines Anticancer Res 2000 20: (5A) 3221–3225
Loe DW, Deeley RG, Cole SP . Biology of the multidrug resistance–associated protein, MRP Eur J Cancer 1996 32A: (6) 945–957
Ishikawa T, Bao JJ, Yamane Y, et al . Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells J Biol Chem 1996 271: (25) 14981–14988
Kuo MT, Bao J, Furuichi M, et al . Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues Biochem Pharmacol 1998 55: (5) 605–615
Cornwell MM, Smith DE . SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity J Biol Chem 1993 268: (26) 19505–19511
Zhu Q, Center MS . Evidence that SP1 modulates transcriptional activity of the multidrug resistance–associated protein gene DNA Cell Biol 1996 15: (2) 105–111
Ohga T, Koike K, Ono M, et al . Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light Cancer Res 1996 56: (18) 4224–4228
Ohga T, Uchiumi T, Makino Y, et al . Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene J Biol Chem 1998 273: (11) 5997–6000
Yu L, Cohen D, Piekarz RL, et al . Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance mdr1b gene J Biol Chem 1993 268: (10) 7520–7526
Sullivan GF, Yang JM, Vassil A, et al . Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells J Clin Invest 2000 105: (9) 1261–1267
Ishikawa T, Kuo MT, Furuta K, et al . The human multidrug resistance-associated protein (MRP) gene family: from biological function to drug molecular design Clin Chem Lab Med 2000 38: (9) 893–897
Torgeman A, Mor-Vaknin N, Zelin E, et al . SP1–p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12- O -tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C Virology 2001 281: (1) 10–20
Levine AJ . p53, the cellular gatekeeper for growth and division Cell 1997 88: (3) 323–331
Horikoshi N, Usheva A, Chen J, et al . Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression Mol Cell Biol 1995 15: (1) 227–234
Lane DP, Benchimol S . p53: oncogene or anti-oncogene? Genes Dev 1990 4: (1) 1–8
Nicoletti ML, Myers TG, Fojo T, et al . Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells Int J Oncol 2001 18: (2) 375–381
Hirose M, Kuroda Y . p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines Cancer Lett 1998 129: (2) 165–171
Galimberti S, Marchetti A, Buttitta F, et al . Multidrug resistance–related genes and p53 expression in human non small cell lung cancer Anticancer Res 1998 18: (4C) 2973–2976
Bahr O, Wick W, Weller M . Modulation of MDR/MRP by wild type and mutant p53 J Clin Invest 2001 107: (5) 643–646
Wartenberg M, Ling FC, Schallenberg M, et al . Down-regulation of intrinsic p-glycoprotein expression multicellular prostate tumor spheroids by reactive oxygen species J Biol Chem 2001 276: (20) 17420–17428
Kirch HC, Flaswinkel S, Rumpf H, et al . Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max Oncogene 1999 18: (17) 2728–2738
Aruoma OI, Halliwell B (eds.) . Molecular Biology of Free Radicals in Human Diseases London: Oica International 1998
Cho S, Urata Y, Iida T, et al . Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B–mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells Biochem Biophys Res Commun 1998 253: (1) 104–108
Kohno T, Yamada Y, Hata T, et al . Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)–mediated apoptosis of adult T cell leukemia cells J Immunol 1996 156: (12) 4722–4728
Klatt P, Molina EP, De Lacoba MG, et al . Redox regulation of c-Jun DNA binding by reversible S-glutathiolation FASEB J 1999 13: (12) 1481–1490
Acknowledgements
This work was supported, in part, by grants-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iida, T., Kijima, H., Urata, Y. et al. Hammerhead ribozyme against γ-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther 8, 803–814 (2001). https://doi.org/10.1038/sj.cgt.7700371
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700371
Keywords
This article is cited by
-
Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation
Journal of Molecular Medicine (2011)
-
Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Cancer Chemotherapy and Pharmacology (2009)